FDA Funding In Cures Bill Complicated By Metrics, Appropriators
Executive Summary
But a Harvard researcher argues to improve drug development, basic research should receive more money because FDA review is not the problem.
You may also be interested in...
Unsure About ‘Breakthrough’-Worthiness? Talk To FDA First
An early, informal conversation between a sponsor and the review division about the supportive data could help reduce the number of ‘breakthrough therapy’ designation requests that are ultimately denied, FDA and sponsors said.
Congressional ‘Cures’ Debate Shifts To FDA Funding
House Democrats say FDA will need more money to be able to handle the responsibilities in the draft bill, while the agency worries reviews could slow without more resources.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.